Not every medicine is getting more expensive at the same rate. Some therapeutic categories are seeing far sharper price growth in 2026 than others. Here's a breakdown of which types of medicines are driving the increases — and why.
1. Specialty and cancer drugs
Specialty medications, including many cancer treatments, remain the single biggest driver of drug spending growth. New launches in oncology tend to enter the market at high price points, and expanded indications for existing cancer drugs mean more patients are being treated with premium-priced therapies.
2. GLP-1 diabetes and weight-loss drugs
GLP-1 agonists — used for both type 2 diabetes and weight management — have become the fastest-growing category in pharmacy spending. Demand has outpaced almost every other drug class, and this growth is expected to accelerate further into 2027 as more indications and formulations reach the market.
3. Vaccines
Several widely used vaccines, including COVID-19, RSV, and shingles shots, are among the products seeing list-price increases in 2026. Because vaccines are often administered seasonally and at scale, even modest per-dose increases add up across public health budgets.
4. Chronic-disease specialty drugs (endocrine and cardiovascular)
Endocrine drugs — covering conditions like diabetes and thyroid disorders — continue to be a major expenditure category. At the same time, several major cardiovascular and metabolic brand drugs are facing downward price pressure from generic and biosimilar competition, showing that the picture isn't one-directional: some categories are rising while others are actually getting cheaper.
5. Categories getting cheaper: biosimilars and generics
It's not all price increases. Biosimilar competition is beginning to meaningfully offset high launch prices in certain specialty categories, and several widely prescribed brand drugs are seeing price decreases as generic competitors enter the market. This is part of why overall pharmacy trend growth moderated slightly in 2025–2026 before an expected pickup in 2026–2027.
What this means for patients
If your prescription falls into a specialty, cancer, or GLP-1 category, expect continued upward price pressure through 2027. If you're on an older brand-name drug that now has generic or biosimilar competition, ask your doctor or pharmacist whether switching could lower your cost without changing your treatment outcome.
Disclaimer: This article is for general informational purposes only and is not medical advice. Always consult your doctor before changing any medication.
0 Comments